• Total Revenue (Q4 2024): $2.5 billion, 3% growth from Q4 2023.
• Total Revenue (Full Year 2024): $9.7 billion, 2% decline from 2023.
• Non-GAAP Diluted EPS (Q4 2024): $3.44, 17% higher than Q4 2023.
• Non-GAAP Diluted EPS (Full Year 2024): $16.47, 12% higher than 2023.
• Free Cash Flow (Q4 2024): $722 million.
• Free Cash Flow (Full Year 2024): $2.7 billion, up from $1.3 billion in 2023.
• MS Product Revenue Decline (Q4 2024): Roughly 8% at actual currency, 9% at constant currency.
• Rare Disease Revenue (Q4 2024): $535 million, 13% growth at actual currency, 15% at constant currency.
• Global SKYCLARYS Revenue (Q4 2024): $102 million, 83% increase from Q4 2023.
• Global SPINRAZA Revenue (Q4 2024): $421 million, 2% growth year over year.
• ZURZUVAE Revenue (Q4 2024): Approximately $23 million.
• LEQEMBI Global In-Market Sales (Q4 2024): Approximately $87 million, 30% sequential growth.
• Non-GAAP Cost of Sales Improvement (Q4 2024): Improved by 300 basis points compared to Q4 2023.
• Non-GAAP Core Operating Expense Increase (Q4 2024): 4% year over year.
• Cash and Net Debt (End of 2024): $2.4 billion cash, $3.9 billion net debt.
• 2025 Revenue Guidance: Expected to decline by a mid-single-digit percentage.
• 2025 Non-GAAP Diluted EPS Guidance: Between $15.25 and $16.25.

• Warning! GuruFocus has detected 6 Warning Signs with BIIB.

Release Date: February 12, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Biogen Inc (NASDAQ:BIIB) launched four first-in-class, disease-modifying products in Alzheimer's, Friedreich's ataxia, depression, and ALS, showcasing their innovation capabilities.
• The company has reprioritized its pipeline, focusing on key projects expected to yield significant developments starting in 2026.
• Biogen Inc (NASDAQ:BIIB) has successfully reduced operating expenses, freeing up resources for growth investments, resulting in improved cash flow.
• Revenue from new product launches in 2024 more than offset the decline in multiple sclerosis product revenue, marking the first core pharma business growth in four years.
• The company is leveraging advanced technologies like AI and genetic testing to identify patients for rare disease treatments, enhancing their market reach.

Negative Points

• Biogen Inc (NASDAQ:BIIB) faces increased competition in the multiple sclerosis market, impacting revenue from this segment.
• The company's total revenue declined by $160 million in 2024, with a significant drop in contract manufacturing revenue.
• Challenges in patient identification and reimbursement, particularly in rare diseases, pose hurdles to revenue growth.
• The potential entry of TYSABRI biosimilars in the US and TECFIDERA generics in Europe could further pressure the MS business.
• Biogen Inc (NASDAQ:BIIB) anticipates a mid-single-digit percentage decline in total revenue for 2025, driven by increased competition and potential biosimilar and generic entries.

Q & A Highlights

Q: What is Biogen's latest thinking on capacity preference and potential timelines for external business development (BD)? How does this balance with the existing pipeline? A: Christopher Viehbacher, CEO, emphasized the importance of reinforcing the pipeline, stating that Biogen is open to collaborations and bringing in assets, particularly in early phases. CFO Michael McDonnell added that Biogen's balance sheet is strong, with significant capacity for smaller or larger deals that make financial sense.

Q: Can you elaborate on the potential impact of blood-based diagnostics for Alzheimer's disease? A: Priya Singhal, Head of Development, explained that accurate diagnosis of Alzheimer's is crucial. Blood-based diagnostics could replace PET scans, providing a more accessible and reimbursable option. Companies like FujireBio have filed for FDA approval, and advancements are expected soon.

Q: How does the Royalty Pharma deal affect Biogen's R&D expenses for 2025? Will there be more such transactions? A: CFO Michael McDonnell stated that the $200 million from Royalty Pharma in 2025 will reduce R&D expenses. CEO Christopher Viehbacher noted that while this model is useful for spreading investment risk, it may not be applicable to every product.

Q: What are the dynamics of SKYCLARYS in the US, and how does Biogen plan to grow revenue? A: CEO Christopher Viehbacher highlighted the use of AI and genetic testing to identify patients and educate physicians about Friedreich's ataxia. He noted that reimbursement is not a major issue in the US, and Biogen is adept at navigating these systems.

Q: Can you provide more details on SPINRAZA's performance in the US? A: CEO Christopher Viehbacher mentioned that SPINRAZA competes in a small, competitive market. The high-dose option and a new device for easier administration are expected to enhance its appeal. CFO Michael McDonnell added that there were no significant inventory issues affecting SPINRAZA's performance.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.